Does Wegovy eventually stop working — and what can you do about it?

Why weight loss with Wegovy slows, and why that is not the same as stopping

The question most people are really asking is: "I've stopped losing weight. Has the drug given up on me?" The honest answer is probably not.

Semaglutide works by activating GLP-1 receptors that regulate appetite and slow how quickly the stomach empties. In the early weeks, that appetite suppression is often dramatic. Over months, the body recalibrates. Metabolic rate adjusts to a lower body weight, energy intake stabilises at a new set point, and the dramatic weekly losses of the first few months become smaller or stop altogether. This is a normal physiological response, not a sign the medicine has lost potency.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants taking semaglutide 2.4mg for 68 weeks. Average weight loss was around 15%. Crucially, most of that loss occurred in the first 52 weeks; the final stretch was largely maintenance. A plateau in month nine or ten, in other words, may simply mean the treatment is doing exactly what it should.

That said, a plateau that arrives very early (say within the first eight weeks at a starter dose) is worth flagging to your prescriber. It may reflect that titration is needed, that a dose increase is appropriate, or that something else is affecting response.

What happens when people stop, the regain picture

This is where the evidence is most important to understand clearly. Wegovy is not a short course that resets your metabolism permanently. The NHS medicines guidance on semaglutide reflects what trial data confirms: when people stop taking it, appetite tends to return to pre-treatment levels and weight regains follow.

STEP 1 extension data tracked participants for a year after stopping semaglutide. On average, roughly two-thirds of the weight lost during the trial returned within twelve months. That is a significant finding. It does not mean Wegovy was not working, it means it was actively working the whole time, and without it the underlying biology reasserts itself.

NICE's recommendation under TA875 notes a maximum of two years of semaglutide on the NHS, within a specialist service. Privately, the clinical question is different: a prescriber assesses whether continued treatment is appropriate for you individually. For many people, the decision about long-term use is genuinely complex, and the Wegovy treatment page covers the licensed context in more detail. Worth sitting with this evidence before drawing conclusions about stopping.

Factors that affect how well semaglutide keeps working

A plateau is not one thing. Several factors can blunt or restore response, and separating them matters before making any decision about continuing, stopping, or escalating treatment.

Dose titration. The starting dose of Wegovy is 0.25mg, a tolerability step. The licensed maintenance dose is 2.4mg (and now 7.2mg with a dedicated pen, approved by the MHRA in April 2026). Some people plateau because they have not yet reached their highest clinically appropriate dose. That is a prescriber conversation, not a self-adjustment.

Lifestyle inputs. Semaglutide reduces appetite; it does not override energy balance completely. If calorie intake drifts upward (sometimes without the person noticing, because appetite cues become less reliable over time) loss stalls. The pen sitting in the fridge door next to the orange juice is still working; the question is what surrounds it. Protein adequacy, sleep quality, and activity level all contribute.

Underlying conditions. Thyroid disorders, insulin resistance, certain medications, and hormonal changes (perimenopause, for instance) can all interfere with the response to weight-loss treatment. A clinical review is the right first step when progress stalls unexpectedly.

If you are wondering more broadly whether Wegovy works at all, or specifically when to expect results to begin, those questions have their own detailed answers. If you want to understand whether Wegovy stops working after a while, including what the longer-term data actually show, that is covered in detail separately.

The decision: continue, adjust, or stop?

This is the frame the question actually calls for. Most people reaching a plateau face a genuine choice, and the evidence points toward a few principles.

If you are maintaining significant weight loss (even without ongoing loss) that is a positive clinical outcome. Obesity is a chronic condition, and stable weight at a healthier point reduces cardiovascular, metabolic, and joint-load risk. Stopping because loss has slowed, rather than because treatment is no longer appropriate, may not be the right call.

If response has genuinely stalled early, or if side effects are making continued use very difficult, a prescriber review is the structured next step. There may be reasons to try a different medicine, to consider a dose change, or to think about other evidence-based weight management options alongside or instead. Our clinical team reviews every case individually, no one-size-fits-all protocol.

The related question of why semaglutide sometimes stops working gets into the mechanistic detail if you want to go further. And if you are weighing up whether Wegovy still makes sense as a private treatment, our free consultation is the place to start that conversation with a prescriber directly. You can also find brand assets such as the Wegovy logo in PNG format on our resources pages.